RELATED: Lilly, BI's Jardiance posts 'amazing' 14% reduction in major CV events J&J had been hoping the trials, dubbed Canvas and Canvas-R, would turn up results that would make physicians more inclined to prescribe the product, not less. After all, SGLT2 rival Jardiance from Eli Lilly and Boehringer Ingelheim has already showed it can cut the combined rate of heart attack, stroke and cardiovascular death in high-risk Type 2 patients, and J&J is crossing its fingers that its med can do the same in an upcoming trial. Now, though, "the increasingly differentiated labels and data to date suggest that …